Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2.
Catania. A A; Grieco. P P; Randazzo. A A; Novellino. E E; Gatti. S S; Rossi. C C; Colombo. G G; Lipton. J M JM
Key Findings
- The dimeric peptide [Ac-CKPV]2 shows strong candidacidal activity in vitro
- It is effective against azole‑resistant Candida species
- NMR and modeling reveal an extended backbone with a beta‑turn‑like structure
Practical Outcomes
- The study points to a promising new antifungal candidate, but it’s still early‑stage research. Biohackers can note the potential of KPV‑based compounds for fungal issues, yet there’s no guidance on safe human use or dosing yet.
Summary
Scientists made a double‑linked version of a tiny peptide called KPV, naming it [Ac-CKV]2, and found it can kill Candida fungi, even strains that resist common antifungal drugs. Their lab work shows the molecule’s shape is stretched out with a small bend, which may help its killing power. However, they only tested it in the lab and didn’t give any dosing or safety info for people.
Abstract
Previous research has shown that the immunomodulatory peptide alpha-melanocyte-stimulating hormone (alpha-MSH) and its carboxy-terminal tripeptide KPV (Lys-Pro-Val alpha-MSH11-13) have antimicrobial influences. By inserting a Cys-Cys linker between two units of KPV, we designed the dimer [Ac-CKPV]2 that showed excellent candidacidal effects in pilot tests and was the subject of further investigations. [Ac-CKPV]2 was active against azole-resistant Candida spp. Therefore, the molecule appeared a promising candidate for therapy of fungal infections and was the subject of a structural study. 1H-NMR and restrained mechanic and dynamic calculations suggest that the peptide adopts an extended backbone structure with a beta-turn-like structure. These results open a pathway to development of additional novel compounds that have candidacidal effects potentially useful against clinical infections.
Study Information
pubmed
2005
10.1111/j.1399-3011.2005.00265.x